Is Illumina, Inc. the Best Immunotherapy Stock to Buy Now?
| DLRHX Fund | USD 27.37 0.02 0.07% |
Slightly above 61% of Delaware Healthcare's investor base is looking to short. The analysis of overall sentiment of trading Delaware Healthcare Fund mutual fund suggests that many investors are alarmed at this time. Delaware Healthcare's investing sentiment can be driven by a variety of factors including economic data, Delaware Healthcare's earnings reports, geopolitical events, and overall market trends.
Delaware |
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Illumina, Inc. stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from 240 billion in 2023 to 1.3 trillion by
Read at finance.yahoo.com
 |
Delaware Healthcare Fundamental Analysis
We analyze Delaware Healthcare's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Delaware Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Delaware Healthcare based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Equity Positions Weight
Equity Positions Weight Comparative Analysis
Delaware Healthcare is currently under evaluation in equity positions weight among similar funds. Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
Delaware Healthcare Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Delaware Healthcare mutual fund to make a market-neutral strategy. Peer analysis of Delaware Healthcare could also be used in its relative valuation, which is a method of valuing Delaware Healthcare by comparing valuation metrics with similar companies.
Peers
Delaware Healthcare Related Equities
| OCLGX | Optimum Large | 0.78 | ||||
| OCIEX | Optimum International | 0.63 | ||||
| WASAX | Ivy Asset | 0.52 | ||||
| OCFIX | Optimum Fixed | 0.34 | ||||
| IMAAX | Ivy Apollo | 0.31 | ||||
| WSGAX | Ivy Small | 0.28 | ||||
| OCLVX | Optimum Large | 0.24 | ||||
| OASGX | Optimum Small-mid | 0.16 | ||||
| OASVX | Optimum Small-mid | 0.13 | ||||
| OCSGX | Optimum Small-mid | 0.13 |
Other Information on Investing in Delaware Mutual Fund
Delaware Healthcare financial ratios help investors to determine whether Delaware Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Delaware with respect to the benefits of owning Delaware Healthcare security.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |